There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis. In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

Around 150,000 people are living with the condition in the UK, while a further 7,100 are newly diagnosed each year ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this form of the ...

The NHS has shared a tweet to raise awareness of multiple sclerosis (MS), an incurable condition that affects the central ...

Andy Blacker, from Ipswich, completed a 300-mile trek for the East Anglian Air Ambulance as part of his ongoing fundraising ...